Cabotegravir 200 mg/mL

DRUG2 trials

Sponsors

ViiV Healthcare

Conditions

HIV Infections

Phase 1

Study to Evaluate Pharmacokinetic (PK), Safety and Tolerability of Cabotegravir (CAB) 400 Milligrams Per Milliliter (mg/mL) Formulation in Healthy Adult Participants

CompletedNCT04484337

ViiV HealthcareHIV Infections

Start: 2020-07-31End: 2023-05-05Updated: 2023-12-04

A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult Participants

RecruitingNCT05418868

ViiV HealthcareHIV Infections

Start: 2022-06-14End: 2027-06-08Target: 214Updated: 2025-12-18

Related Papers

A Randomized Phase 1 Study Evaluating Pharmacokinetics, Safety, and Tolerability of a High‐Concentration, Long‐Acting Cabotegravir Formulation in Adults Without HIV

Clinical Pharmacology in Drug Development2025-04-293 citations